Errata - English

Footnote a of Table 1: Change
Ethyl (12RS,13aSR,13bSR)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (ethyl vincaminate).
to:
Ethyl (12S,13aS,13bS)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (ethyl vincaminate).
AND
Footnoteb of Table 1: Change
Methyl (13aS,13bS)-13a-ethyl-9-methoxy-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine).
to:
Methyl (13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine).
AND
Footnote d of Table 1: Change
Ethyl (12RS,13aRS,13bRS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine).
to:
Ethyl (12R,13aS,13bS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine).

Change
Delete the following
^▲•USP Reference Standards <11>
USP Retinyl Acetate RS
USP Retinyl Palmitate RS
_{▲(CN 1-May-2018)}
to:
•USP Reference Standards <11>
USP Retinyl Acetate RS
USP Retinyl Palmitate RS

Line 7 of Analysis: Change
Result = (r_U/r_S) × (C/W) × (V/D) × U × (100/L)
to:
Result = (r_U/r_S) × (C/W) × D × U × (100/L)
AND
Line 16 of the Analysis: Delete
V = volume of the Sample solution (mL)

In Biotin, Method 3/Solid-phase extraction: Change
anion-xchange
to:
anion-exchange
AND
In the Calculate statement in Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis: Delete
, calcium pantothenate (C₁₈H₃₂CaN₂O₁₀), and folic acid (C₁₉H₁₉N₇O₆),
AND
In the Calculate statement in Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis: Delete
, calcium pantothenate (C₁₈H₃₂CaN₂O₁₀), and folic acid (C₁₉H₁₉N₇O₆),
AND
In the Calculate statement in Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis: Add
ascorbic acid (C₆H₈O₆),

In the Calculate statement in Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis: Delete
, calcium pantothenate (C₁₈H₃₂CaN₂O₁₀), and folic acid (C₁₉H₁₉N₇O₆),
AND
In the Calculate statement in Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis: Delete
, calcium pantothenate (C₁₈H₃₂CaN₂O₁₀), and folic acid (C₁₉H₁₉N₇O₆),
AND
In the Calculate statement in Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis: Add
ascorbic acid (C₆H₈O₆),

In USP Zileuton Related Compound A RS: Change
N-(1-Benzo-[b]thien-2-ylethyl)urea.
C₁₁H₁₂N₂OS 220.30
to:
N-(1-Benzo-[b]thien-2-ylethyl)urea;
Also known as 1-[1-(Benzo[b]thiophen-2-yl)ethyl]urea.
C₁₁H₁₂N₂OS 220.29
AND
In USP Zileuton Related Compound B RS: Change
2-(Benzo[b]thien-2-oyl)benzo[b]thiopene.
C₁₇H₁₀OS₂ 294.40
to:
2-(Benzo[b]thien-2-oyl)benzo[b]thiophene;
Also known as Bis(benzo[b]thiophen-2-yl)methanone.
C₁₇H₁₀OS₂ 294.39
AND
In USP Zileuton Related Compound C RS: Change
1-Benzo-[b]thien-2-ylethanone.
C₁₀H₈OS 176.24
to:
1-Benzo-[b]thien-2-ylethanone;
Also known as 1-(Benzo[b]thiophen-2-yl)ethan-1-one.
C₁₀H₈OS 176.23

In Solution A: Change
0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well.
to:
0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of 0.5 N hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well.

In Dissolution 〈711〉/Test 1/Tier 1/Phosphate buffer, pH 7.5: Change
sodium hydroxide
to:
sodium hydroxide solution
AND
In Dissolution 〈711〉/Test 1/Tier 1/Analysis: Change
449.40
to:
449.39
AND
In Dissolution 〈711〉/Test 1/Tier 2/Solution A and Solution B: Change
sodium hydroxide
to:
sodium hydroxide solution
AND
In Dissolution 〈711〉/Test 2/Tier 2/Analysis: Change
449.40
to:
449.39
AND
In Dissolution 〈711〉/Test 3/Tier 2/Analysis: Change
449.40
to:
449.39

In USP Ziprasidone Related Compound F RS: Change
2-(2-Amino-5-{2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetic acid.
C₂₁H₂₃ClN₄O₂S 430.95
to:
Sodium 2-(2-amino-5-{2-[4-(benzisothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetate monohydrate;
Also known as Sodium 2-(2-amino-5-{2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetate monohydrate.
C₂₁H₂₂ClN₄NaO₂S · H₂O 470.95

In the second Calculate statement: Change
chloroindolinone and ziprasidone related compound F
to:
chloroindolinone, ziprasidone related compound F, and any individual unspecified impurity
AND
In the second variable definition list: Change
F = relative response factor for chloroindolinone or ziprasidone related compound F from Table 3
to:
F = relative response factor for chloroindolinone or ziprasidone related compound F or any individual unspecified impurity from Table 3

In the second variable definition in Analysis: Change
r_U = peak response of chloroindolinone or ziprasidone related compound F from the Sample solution
to:
r_U = peak response of chloroindolinone, ziprasidone related compound F, or any unspecified impurity from the Sample solution

In Organic Impurities/Solution B: Change
Acetonitrile, methanol, and Buffer (55:5:40). Adjust with potassium hydroxide TS to a pH of 6.0.
to:
Acetonitrile, methanol, and Buffer (55:5:40). Adjust with potassium hydroxide solution to a pH of 6.0.
AND
In both equations in Organic Impurities/Analysis: Change
449.40
to:
449.39

Change
(see Mid-Infrared Spectroscopy 〈854〉, Ultraviolet-Visible Spectroscopy 〈857〉, X-Ray Powder Diffraction 〈941〉, Near-Infrared Spectroscopy—Theory and Practice 〈1856〉, and Raman Spectroscopy 〈858〉.
to:
(see Mid-Infrared Spectroscopy 〈854〉, Near-Infrared Spectroscopy 〈856〉, Ultraviolet-Visible Spectroscopy 〈857〉, Raman Spectroscopy 〈858〉, and X-Ray Powder Diffraction 〈941〉).